|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pao W and Hutchinson KE: Chipping away at
the lung cancer genome. Nat Med. 18:349–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morgensztern D, Pennell NA, Subramanian J
and Govindan R: Summary of presentations from the 46th annual
meeting of the American Society Of Clinical Oncology (2010): Focus
on developmental therapeutics related to lung cancer. Clin Lung
Cancer. 12:94–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heist RS and Engelman JA: SnapShot:
Non-small cell lung cancer. Cancer Cell. 21:448–448e2. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsieh JC, Kodjabachian L, Rebbert ML,
Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB and Nathans J:
A new secreted protein that binds to Wnt proteins and inhibits
their activities. Nature. 398:431–436. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malinauskas T, Aricescu AR, Lu W, Siebold
C and Jones EY: Modular mechanism of Wnt signaling inhibition by
Wnt inhibitory factor 1. Nat Struct Mol Biol. 18:886–893. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Amerongen R and Nusse R: Towards an
integrated view of Wnt signaling in development. Development.
136:3205–3214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mazieres J, He B, You L, Xu Z and Jablons
DM: Wnt signaling in lung cancer. Cancer Lett. 222:1–10. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Licchesi JD, Westra WH, Hooker CM, Machida
EO, Baylin SB and Herman JG: Epigenetic alteration of Wnt pathway
antagonists in progressive glandular neoplasia of the lung.
Carcinogenesis. 29:895–904. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wissmann C, Wild PJ, Kaiser S, Roepcke S,
Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F,
Hartmann A, et al: WIF1, a component of the Wnt pathway, is
down-regulated in prostate, breast, lung, and bladder cancer. J
Pathol. 201:204–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mazieres J, He B, You L, Xu Z, Lee AY,
Mikami I, Reguart N, Rosell R, McCormick F and Jablons DM: Wnt
inhibitory factor-1 is silenced by promoter hypermethylation in
human lung cancer. Cancer Res. 64:4717–4720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Korobko EV, Kalinichenko SV, Shepelev MV,
Zborovskaia IB, Allakhverdiev AK, Zinov'eva MV, Vinogradova TV,
Sverdlov ED and Korobko IV: Suppression of the WIF1 transcript and
protein in non-small cell lung carcinomas. Mol Gen Mikrobiol
Virusol. 22:53–58. 2007.In Russian.
|
|
13
|
Yang TM, Leu SW, Li JM, Hung MS, Lin CH,
Lin YC, Huang TJ, Tsai YH and Yang CT: WIF-1 promoter region
hypermethylation as an adjuvant diagnostic marker for non-small
cell lung cancer-related malignant pleural effusions. J Cancer Res
Clin Oncol. 135:919–924. 2009. View Article : Google Scholar
|
|
14
|
Yoshino M, Suzuki M, Tian L, Moriya Y,
Hoshino H, Okamoto T, Yoshida S, Shibuya K and Yoshino I: Promoter
hypermethylation of the p16 and Wif-1 genes as an independent
prognostic marker in stage IA non-small cell lung cancers. Int J
Oncol. 35:1201–1209. 2009.PubMed/NCBI
|
|
15
|
Gao Z, Xu Z, Hung MS, Lin YC, Wang T, Gong
M, Zhi X, Jablon DM and You L: Promoter demethylation of WIF-1 by
epigallocatechin-3-gallate in lung cancer cells. Anticancer Res.
29:2025–2030. 2009.PubMed/NCBI
|
|
16
|
Kim J, You L, Xu Z, Kuchenbecker K, Raz D,
He B and Jablons D: Wnt inhibitory factor inhibits lung cancer cell
growth. J Thorac Cardiovasc Surg. 133:733–737. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng Y, Yu B, Cheng Q, Jin J, You H, Ke R,
Tang N, Shen Q, Shu H, Yao G, et al: Epigenetic silencing of WIF-1
in hepatocellular carcinomas. J Cancer Res Clin Oncol.
136:1161–1167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawakami K, Hirata H, Yamamura S, Kikuno
N, Saini S, Majid S, Tanaka Y, Kawamoto K, Enokida H, Nakagawa M,
et al: Functional significance of Wnt inhibitory factor-1 gene in
kidney cancer. Cancer Res. 69:8603–8610. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Zhou B, Liu Y, Chen K, Bao P,
Wang Y, Wang J, Zhou Z, Sun X and Li Y: Wnt inhibitory factor-1
functions as a tumor suppressor through modulating Wnt/β-catenin
signaling in neuroblastoma. Cancer Lett. 348:12–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao C, Cao W, Bao L, Zuo W, Xie G, Cai T,
Fu W, Zhang J, Wu W, Zhang X, et al: Autophagy negatively regulates
Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol.
12:781–790. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren J, Yu C, Wu S, Peng F, Jiang Q, Zhang
X, Zhong G, Shi H, Chen X, Su X, et al: Cationic liposome mediated
delivery of FUS1 and hIL-12 coexpression plasmid demonstrates
enhanced activity against human lung cancer. Curr Cancer Drug
Targets. 14:167–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dings RP, Yokoyama Y, Ramakrishnan S,
Griffioen AW and Mayo KH: The designed angiostatic peptide anginex
synergis-tically improves chemotherapy and antiangiogenesis therapy
with angiostatin. Cancer Res. 63:382–385. 2003.PubMed/NCBI
|
|
23
|
Kabeya Y, Mizushima N, Ueno T, Yamamoto A,
Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a
mammalian homologue of yeast Apg8p, is localized in autophagosome
membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang YP, Liang ZQ, Gu ZL and Qin ZH:
Molecular mechanism and regulation of autophagy. Acta Pharmacol
Sin. 26:1421–1434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Templeton NS, Lasic DD, Frederik PM, Strey
HH, Roberts DD and Pavlakis GN: Improved DNA: Liposome complexes
for increased systemic delivery and gene expression. Nat
Biotechnol. 15:647–652. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin YC, You L, Xu Z, He B, Yang CT, Chen
JK, Mikami I, Clément G, Shi Y, Kuchenbecker K, et al: Wnt
inhibitory factor-1 gene transfer inhibits melanoma cell growth.
Hum Gene Ther. 18:379–386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu J, Dong A, Fernandez-Ruiz V, Shan J,
Kawa M, Martínez-Ansó E, Prieto J and Qian C: Blockade of Wnt
signaling inhibits angiogenesis and tumor growth in hepatocellular
carcinoma. Cancer Res. 69:6951–6959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang Y, Simoneau AR, Liao WX, Yi G, Hope
C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, et al: WIF1, a Wnt
pathway inhibitor, regulates SKP2 and c-myc expression leading to
G1 arrest and growth inhibition of human invasive urinary bladder
cancer cells. Mol Cancer Ther. 8:458–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu J, Fang J, Yang Z, Chen F, Liu J and
Wang Y: Wnt inhibitory factor-1 regulates glioblastoma cell cycle
and proliferation. J Clin Neurosci. 19:1428–1432. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klionsky DJ: Autophagy revisited: A
conversation with Christian de Duve. Autophagy. 4:740–743. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mathew R, Karantza-Wadsworth V and White
E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kondo Y and Kondo S: Autophagy and cancer
therapy. Autophagy. 2:85–90. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Amaravadi RK and Thompson CB: The roles of
therapy-induced autophagy and necrosis in cancer treatment. Clin
Cancer Res. 13:7271–7279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang ZJ, Chee CE, Huang S and Sinicrope F:
Autophagy modulation for cancer therapy. Cancer Biol Ther.
11:169–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen S, Kepp O, Michaud M, Martins I,
Minoux H, Métivier D, Maiuri MC, Kroemer RT and Kroemer G:
Association and dissociation of autophagy, apoptosis and necrosis
by systematic chemical study. Oncogene. 30:4544–4556. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maycotte P and Thorburn A: Autophagy and
cancer therapy. Cancer Biol Ther. 11:127–137. 2011. View Article : Google Scholar :
|
|
37
|
Fulda S: Autophagy and cell death.
Autophagy. 8:1250–1251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park EJ, Choi KS and Kwon TK:
β-Lapachone-induced reactive oxygen species (ROS) generation
mediates autophagic cell death in glioma U87 MG cells. Chem Biol
Interact. 189:37–44. 2011. View Article : Google Scholar
|
|
39
|
Crighton D, Wilkinson S, O'Prey J, Syed N,
Smith P, Harrison PR, Gasco M, Garrone O, Crook T and Ryan KM:
DRAM, a p53-induced modulator of autophagy, is critical for
apoptosis. Cell. 126:121–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bilic J, Huang YL, Davidson G, Zimmermann
T, Cruciat CM, Bienz M and Niehrs C: Wnt induces LRP6 signalosomes
and promotes dishevelled-dependent LRP6 phosphorylation. Science.
316:1619–1622. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wei Q, Zhao Y, Yang ZQ, Dong QZ, Dong XJ,
Han Y, Zhao C and Wang EH: Dishevelled family proteins are
expressed in non-small cell lung cancer and function differentially
on tumor progression. Lung Cancer. 62:181–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Uematsu K, He B, You L, Xu Z, McCormick F
and Jablons DM: Activation of the Wnt pathway in non small cell
lung cancer: Evidence of dishevelled overexpression. Oncogene.
22:7218–7221. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He B, You L, Uematsu K, Xu Z, Lee AY,
Matsangou M, McCormick F and Jablons DM: A monoclonal antibody
against Wnt-1 induces apoptosis in human cancer cells. Neoplasia.
6:7–14. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nahta R and O'Regan RM: Evolving
strategies for overcoming resistance to HER2-directed therapy:
Targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer. 10(Suppl
3): S72–S78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Racanelli AC, Rothbart SB, Heyer CL and
Moran RG: Therapeutics by cytotoxic metabolite accumulation:
Pemetrexed causes ZMP accumulation, AMPK activation, and mammalian
target of rapamycin inhibition. Cancer Res. 69:5467–5474. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Margolin K, Longmate J, Baratta T, Synold
T, Christensen S, Weber J, Gajewski T, Quirt I and Doroshow JH:
CCI-779 in metastatic melanoma: A phase II trial of the California
Cancer Consortium. Cancer. 104:1045–1048. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Crazzolara R, Cisterne A, Thien M, Hewson
J, Baraz R, Bradstock KF and Bendall LJ: Potentiating effects of
RAD001 (Everolimus) on vincristine therapy in childhood acute
lymphoblastic leukemia. Blood. 113:3297–3306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lin CI, Whang EE, Donner DB, Du J, Lorch
J, He F, Jiang X, Price BD, Moore FD Jr and Ruan DT: Autophagy
induction with RAD001 enhances chemosensitivity and
radiosensitivity through Met inhibition in papillary thyroid
cancer. Mol Cancer Res. 8:1217–1226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Marinov M, Ziogas A, Pardo OE, Tan LT,
Dhillon T, Mauri FA, Lane HA, Lemoine NR, Zangemeister-Wittke U,
Seckl MJ, et al: AKT/mTOR pathway activation and BCL-2 family
proteins modulate the sensitivity of human small cell lung cancer
cells to RAD001. Clin Cancer Res. 15:1277–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Thompson LA, Kim M, Wenger SD and O'Bryant
CL: Everolimus: A new treatment option for advanced pancreatic
neuroendocrine tumors. Ann Pharmacother. 46:1212–1219. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tan X, Liu Y, Hou J and Cao G: Targeted
therapies for renal cell carcinoma in Chinese patients: Focus on
everolimus. Onco Targets Ther. 8:313–321. 2015.PubMed/NCBI
|
